Archive: 08/10/2021
ATR inhibitor RP-3500 demonstrates safety and early clinical benefit
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021